Ionis Pharmaceuticals (IONS) Q3 2026 earnings review
Ionis cuts its Tryngolza sales plan while Dawnzera grows
Ionis Pharmaceuticals, a developer of genetic medicines for rare and heart diseases, saw its main drug launch stumble while partner payments and a second launch filled the gap. Third-quarter revenue jumped 55% from a year ago to $243 million as research fees and Dawnzera sales rose. However, chief executive Brett P. Monia cut the 2026 sales outlook for blood-fat drug Tryngolza in half because doctors and insurers are adopting the treatment slowly.
| Total revenue | $243M +55% from a year ago |
|---|---|
| Tryngolza 2026 sales outlook | Cut to ~$50M prior plan: $100M to $110M |
| Dawnzera net sales | $37M +42% from last quarter |
| Full-year revenue outlook | Unchanged middle of the range: $888M |
⚖️ Verdict: 🔴 Bearish
The story got worse because Tryngolza is the centerpiece of the company's push to sell its own medicines to large patient groups. By our math, the new $50 million full-year target leaves about $9 million of Tryngolza sales for the fourth quarter, matching the third quarter with no growth at all. On the bright side, fast growth from swelling treatment Dawnzera and rising Spinraza royalties let finance chief Elizabeth L. Hougen hold the full-year revenue and loss plans steady.
The question now is whether Tryngolza's slow start comes from temporary insurance paperwork or weaker demand from doctors after the company's price cut. If paperwork is the only hurdle, revenue will climb in early 2027 when new insurance contracts start; if doctors are hesitant, multi-billion-dollar sales targets are out of reach. Early 2027 prescription trends and the 2027 sales outlook will settle the debate.
🐂 Bull Case
Dawnzera Sales Rise 42% From Last Quarter
Dawnzera, an injection that prevents attacks of hereditary angioedema (a rare swelling disorder), is now carrying the commercial business. Ionis Pharmaceuticals called the medicine "a continuing driver of year-over-year revenue growth" and kept its full-year product sales outlook at $110 million to $120 million.
United States net sales reached $37 million in the third quarter, up 42.3% from $26 million in the second quarter by our math. That brings nine-month sales to $79 million, while regulators in Europe and Canada also cleared the drug for sale.
Because nine-month sales already sit at $79 million, the biotechnology company needs only $36 million in the fourth quarter to hit the middle of its full-year range by our math. That means Dawnzera can meet its target even if quarterly sales do not grow in the final three months of the year.
What to watch: fourth-quarter Dawnzera net sales and the 2027 product outlook on the next earnings call. Further quarterly gains above $37 million would show that patients are still switching from older preventive treatments.
Partner Payments and Spinraza Keep Revenue Plan Intact
Payments from drug development partners and royalties on Spinraza, a Biogen-marketed treatment for spinal muscular atrophy, covered the shortfall from Ionis's own triglyceride launch. Finance chief Elizabeth L. Hougen said strong research revenue and Dawnzera kept the drugmaker on track for its full-year targets.
- Collaborative agreement revenue: $103 million, up from $31 million a year ago
- Spinraza royalty revenue: $69 million, up 23.2% from a year ago on $461 million of global sales
- Total third-quarter revenue: $243 million, up 54.8% from a year ago
Those partner streams allowed the California company to hold its full-year revenue outlook at $875 million to $900 million despite cutting its Tryngolza forecast by $55 million at the middle of the range.
What to watch: fourth-quarter research and development revenue. By our math, the full-year outlook leaves $130.5 million of total revenue for the fourth quarter, down 35.7% from a year ago because partner milestone payments vary from quarter to quarter.
Three Approvals and Two Trial Wins Expand Pipeline
Ionis is adding new revenue sources from both its wholly owned drugs and its partnered programs. Chief executive Brett P. Monia noted that Zanvastro, a treatment for the rare neurological disorder Alexander disease, marks the company's "first independent neurology launch".
Zanvastro recorded its first $2 million of sales in the third quarter, while partner GSK won approval in the United States, Japan and Canada for Hibsago in chronic hepatitis B. Two other partnered drugs, sefaxersen for kidney disease (cutting protein in the urine by 43.1%) and ulefnersen for a genetic form of amyotrophic lateral sclerosis, also met their main Phase 3 trial goals.
Each approval triggers milestone payments and future royalty streams that carry almost no marketing cost for the creator. What to watch: regulatory filing dates for sefaxersen and ulefnersen in 2027, which will set the schedule for the next wave of royalty income.
🐻 Bear Case
Tryngolza Outlook Cut in Half on Slow Launch
Tryngolza, a monthly injection to lower dangerously high blood fats known as severe hypertriglyceridemia (sHTG) and prevent pancreas inflammation, is the centerpiece of the company's commercial shift. "While initial sales progress has been more gradual than anticipated, we are encouraged by the underlying launch fundamentals," Monia said, while Hougen still projected "multi-billion-dollar peak sales".
Ionis cut its 2026 Tryngolza net sales outlook from $100 million to $110 million down to about $50 million, a 52.4% reduction from the middle of the prior range by our math. The company blamed the early work of "establishing a new treatment paradigm" after third-quarter sales reached only $9 million, down 71.9% from $32 million a year ago following an April price cut.
The numbers contradict the upbeat talk about launch momentum. With nine-month sales at $41 million, the new $50 million full-year target leaves about $9 million for the fourth quarter by our math, meaning sales in the second full quarter of the broader launch will not grow at all from the third quarter.
What to watch: fourth-quarter Tryngolza sales and 2027 insurance coverage updates on the year-end call. A reading stuck near $9 million would show that insurer paperwork and the lower price are holding back revenue even as more doctors write prescriptions.
Wainua Royalties Fall and Heart Trials Slip
Ionis relies on partnered heart medicines to help reach its goal of breaking even on cash flow in 2028. Wainua, a drug sold with AstraZeneca for nerve damage caused by transthyretin amyloidosis, was meant to expand into the much larger heart-damage form of the disease.
In August, the Phase 3 heart study "missed the primary composite endpoint in the overall population", showing a benefit only in patients not taking existing stabilizers. Meanwhile, Wainua royalty revenue dropped to $7 million in the third quarter, down 56.3% from $16 million in the second quarter by our math, and the release's milestone table marked the Phase 3 readout for Novartis-partnered heart drug pelacarsen as not achieved for 2026.
Losing the broad heart indication leaves Wainua competing in nerve damage against a rival drug that treats both conditions, which is already hurting royalties. What to watch: whether AstraZeneca files Wainua for single-drug heart use and when Novartis reports pelacarsen trial results, as losing both heart opportunities would delay cash-flow breakeven.
Launch Costs Rise as Fourth-Quarter Loss Widens
Building a sales force to market three independent drugs at once is driving up overhead costs while research spending stays flat. Selling, general and administrative expenses — the cost of the sales force and corporate overhead — jumped 58.8% from a year ago to $154 million, rising 1.6 percentage points to 63.4% of revenue by our math.
Research, development and patent expenses dipped 0.9% to $216 million, falling 50.0 percentage points as a share of revenue to 88.9% because total revenue grew. Even so, the nine-month operating loss excluding one-offs (stock-based compensation) reached $218 million against a full-year loss outlook of $425 million to $475 million.
By our math, that full-year plan leaves an operating loss excluding one-offs of $232 million for the fourth quarter alone, more than double the $87 million loss in the third quarter. What to watch: 2027 expense plans on the next call, which will show if sales costs keep climbing faster than product sales.
👓 Other Themes
Follow-On Triglyceride Drug ION775 Enters Phase 2
While rolling out monthly Tryngolza, the drugmaker moved ION775, an experimental RNA medicine for high triglycerides that patients might take only twice a year or less, into a Phase 2 trial. Positive Phase 1 results presented in August showed strong fat lowering with longer gaps between doses, which could later defend the franchise against less frequent rival injections.
💲 Other KPIs
Cash and short-term investments fell by $171 million from $2,055 million in the second quarter by our math, and are down from $2,677 million at the end of 2025. The year-to-date drop came from paying off $432 million of convertible debt in April and funding ongoing operating losses, but the balance remains well above the $1.6 billion year-end target.
Total deferred contract revenue — upfront cash from partners that the company has not yet earned as revenue — fell 28.3% from $166 million at the end of 2025 by our math ($70 million current and $49 million long-term). The balance shrank from $137 million in the second quarter as the drugmaker booked partner research revenue.
Shares used to calculate net loss per share rose 3.8% from 160 million a year ago by our math, after holding at 165 million in the first and second quarters of 2026. The higher share count reflects employee stock awards, while contracts receivable owed by partners climbed 33.3% since year-end to $88 million.
🔮 Guidance
Unchanged. The middle of the range sits at $887.5 million, down 6.0% from reported 2025 revenue of $944 million, or up 33.7% by our math when excluding last year's one-time $280 million license fee from Ono Pharmaceutical. By our math, that leaves $130.5 million for the fourth quarter, down 35.7% from a year ago. Management raised this target by $75 million in the first quarter and held it twice since.
Cut. Management lowered the target by 52.4% from the middle of the prior range, leaving full-year sales down 53.7% from the $108 million recorded in 2025 by our math. With $41 million booked in the first nine months, the new plan leaves about $9 million for the fourth quarter, matching the third quarter's $9 million despite a full quarter of marketing for the broader high-triglyceride use.
Unchanged. The plan calls for $115 million at the middle of the range, up from $8 million during its initial launch months in 2025. By our math, subtracting $79 million of nine-month sales leaves $36 million for the fourth quarter, just below the $37 million delivered in the third quarter, making the full-year target look easily reachable.
Unchanged. The outlook points to a $450 million loss at the middle of the range, wider than the $248 million loss in 2025 when the one-time Ono license fee boosted results. By our math, after a $218 million loss across the first nine months, the plan implies a $232 million loss in the fourth quarter as lower implied partner revenue meets rising launch costs.
Unchanged. The company still expects to finish 2026 with more than $1.6 billion in cash and short-term investments, down from $2.68 billion at the end of 2025. Sitting at $1.88 billion on September 30, the balance can absorb up to $284 million of fourth-quarter cash burn and still meet the floor.
❓ Key Questions
Why do implied fourth-quarter Tryngolza sales stay at $9 million?
With nine-month sales at $41 million, the $50 million full-year target implies $9 million in the fourth quarter, matching the third quarter. Investors need to know whether slow insurer approvals, free-drug bridge programs, or deeper price discounts are holding back revenue growth.
Why did Pelacarsen Phase 3 data slip past 2026?
The milestone table marks the Phase 3 readout and U.S. filing for Novartis-partnered heart drug pelacarsen as not achieved in 2026, without a 2027 dot. Because this trial passes when enough heart attacks occur, a slower event rate changes the timeline for milestone payments.
What caused Wainua royalties to drop 56% from last quarter?
Wainua royalty revenue fell from $16 million in the second quarter to $7 million in the third, even though partner AstraZeneca's global sales of the drug only edged down from $70 million to $68 million. Management did not explain why the royalty rate fell.
Can Ionis still break even in 2028 after the Tryngolza cut?
Management reaffirmed its goal of sustained positive cash flow, which it previously set for 2028. With Tryngolza starting slowly, Wainua missing its broad heart goal, and pelacarsen delayed, the 2028 math now rests much more heavily on Dawnzera and 2027 payer access.